<HashMap><database>biostudies-literature</database><scores/><additional><submitter>Kefas B</submitter><funding>NCI NIH HHS</funding><pagination>1652-63</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC3829588</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>15(12)</volume><pubmed_abstract>&lt;h4>Background&lt;/h4>Despite advances in the treatment of the most aggressive form of brain tumor, glioblastoma, patient prognosis remains disappointing. This failure in treatment has been attributed to dysregulated oncogenic pathways, as observed in other tumors. We and others have suggested the use of microRNAs (miRs) as therapeutic tools able to target multiple pathways in glioblastoma.&lt;h4>Methods&lt;/h4>This work features PCR quantification of miRs and transient transfection of many glioblastoma cell lines with miRs, followed by cell number analysis, trypan blue staining, alamarBlue assay of cell viability, caspase-3/-7 activity assay, immunoblot of cleaved poly(ADP-ribose) polymerase and fluorescence activated cell sorting and imaging of apoptotic nuclei, cell invasion assays, MRIs of glio</pubmed_abstract><journal>Neuro-oncology</journal><pubmed_title>A miR-297/hypoxia/DGK-α axis regulating glioblastoma survival.</pubmed_title><pmcid>PMC3829588</pmcid><funding_grant_id>R01CA136803</funding_grant_id><funding_grant_id>P30 CA044579</funding_grant_id><pubmed_authors>Frisbee A</pubmed_authors><pubmed_authors>Abounader R</pubmed_authors><pubmed_authors>Purow B</pubmed_authors><pubmed_authors>Floyd DH</pubmed_authors><pubmed_authors>Guessous F</pubmed_authors><pubmed_authors>Kefas B</pubmed_authors><pubmed_authors>Dominguez C</pubmed_authors><pubmed_authors>Comeau L</pubmed_authors><pubmed_authors>Dipierro CG</pubmed_authors></additional><is_claimable>false</is_claimable><name>A miR-297/hypoxia/DGK-α axis regulating glioblastoma survival.</name><description>&lt;h4>Background&lt;/h4>Despite advances in the treatment of the most aggressive form of brain tumor, glioblastoma, patient prognosis remains disappointing. This failure in treatment has been attributed to dysregulated oncogenic pathways, as observed in other tumors. We and others have suggested the use of microRNAs (miRs) as therapeutic tools able to target multiple pathways in glioblastoma.&lt;h4>Methods&lt;/h4>This work features PCR quantification of miRs and transient transfection of many glioblastoma cell lines with miRs, followed by cell number analysis, trypan blue staining, alamarBlue assay of cell viability, caspase-3/-7 activity assay, immunoblot of cleaved poly(ADP-ribose) polymerase and fluorescence activated cell sorting and imaging of apoptotic nuclei, cell invasion assays, MRIs of glio</description><dates><release>2013-01-01T00:00:00Z</release><publication>2013 Dec</publication><modification>2025-04-05T14:23:24.624Z</modification><creation>2019-03-27T03:08:39Z</creation></dates><accession>S-EPMC3829588</accession><cross_references><pubmed>24158111</pubmed><doi>10.1093/neuonc/not118</doi></cross_references></HashMap>